Tempest Therapeutics Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including federal healthcare benefit programs such as Medicaid and Medicare. Its clients include healthcare professionals such as physicians, dentists, optometrists, podiatrists, chiropractors, physician assistants, nurse practitioners, and teaching hospitals, which receive payments or transfers of value from prescription drug manufacturers. The company operates within federal and state healthcare programs and related regulatory environments.
In a groundbreaking turn of events, Tempest Therapeutics, Inc. has just been awarded Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for its innovative treatment, amezalpat (TPST1120), aimed at combating hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. This recognition not only showcases the potential of amezalpat a selective PPAR antagonist but also highlights an important step forward in the fight against a disease that has long defied effective therapeutics.Amezalpat stands out in a crowded oncology landscape due to its unique mechanism of action. Recent data unveiled by Tempest at the 2025 AACR Annual Meeting revealed its ability to reduce tumor-promoting imm...
Tempest Therapeutics Expands Workforce Incentives with Stock Option Grants under Nasdaq Listing Rule 5635(c)(4) In a significant move that reflects its ongoing commitment to fostering talent and promoting growth within its ranks, Tempest Therapeutics, Inc. (Nasdaq: TPST), a pioneering clinical-stage biotechnology firm specializing in the development of first-in-class targeted and immune-mediated therapeutics for cancer treatment, has announced the issuance of nonqualified stock options to one of its employees. This decision was made in accordance with Nasdaq Listing Rule 5635(c)(4), which allows companies to grant stock options as a means of attracting and retaining skilled professionals.On December 6, 2024,...
Tempest Therapeutics, a clinical-stage oncology company, has unveiled new survival data for their groundbreaking therapeutic drug, amezalpat (TPST-1120). The data shows a significant improvement in median overall survival (OS) when amezalpat is combined with atezolizumab and bevacizumab, compared to the use of atezolizumab and bevacizumab alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC). This exciting development offers new hope for patients battling this aggressive form of liver cancer.The ongoing global randomized Phase 1b/2 clinical study conducted by Tempest Therapeutics has demonstrated a remarkable six-month improvement in median overall survi...
Tempest Therapeutics, Inc., a leading clinical-stage biotechnology company, recently presented new preclinical data at the Society for Immunotherapy of Cancer (SITC) 2024 Spring Scientific Meeting. The data showcased the potent anti-tumor activity of their first-in-class targeted and immune-mediated therapeutic, TPST-1120, in various cancer models. The positive results, both from preclinical studies and clinical trials, reinforce the potential of TPST-1120 as an effective treatment for cancer patients.New Preclinical Data Supports TPST-1120 s Anti-tumor Activity:The poster presentation by Tempest Therapeutics highlighted the preclinical data demonstrating the potent anti-tumor activity of TPST-1120. The stud...
Renal Cell Carcinoma (RCC) accounts for approximately 3% of all adult cancers and remains a significant health burden worldwide. With limited treatment options available, there is a pressing need for innovative therapeutic strategies to combat this aggressive disease. In this article, we explore the recent announcement made by Tempest Therapeutics, Inc. regarding the upcoming presentation of preclinical data for their novel compound, TPST-1120, at the American Association for Cancer Research (AACR) Annual Meeting.TPST-1120: A Potent Weapon Against RCC:Tempest Therapeutics, a renowned clinical-stage biotechnology company, has been at the forefront of developing targeted and immune-mediated therapeutics to fig...
Tempest Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including federal healthcare benefit programs such as Medicaid and Medicare. Its clients include healthcare professionals such as physicians, dentists, optometrists, podiatrists, chiropractors, physician assistants, nurse practitioners, and teaching hospitals, which receive payments or transfers of value from prescription drug manufacturers. The company operates within federal and state healthcare programs and related regulatory environments.
Sources:
Tempest Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Tempest Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Tempest Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
